Toll Free: 1-888-928-9744

Diabetic Nephropathy Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 309 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Nephropathy Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Diabetic Nephropathy Global Clinical Trials Review, H1, 2016" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Five Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Diabetic Nephropathy Therapeutics Clinical Trials 27 Prominent Drugs 29 Latest Clinical Trials News on Diabetic Nephropathy 30 May 13, 2016: Serodus announces positive opinion from Data Safety Monitoring Board on SER150 Ph2a study 30 Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin 30 Clinical Trial Profile Snapshots 32 Appendix 306 Abbreviations 306 Definitions 306 Research Methodology 307 Secondary Research 307 About GlobalData 308 Contact Us 308 Disclaimer 308 Source 309
List of Tables
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region, 2016* 6 Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9 Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12 Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13 Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14 Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17 Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29


List of Figures
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9 Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11 Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12 Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13 Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14 Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17 Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 GlobalData Methodology 307

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify